Pneumocystis

Clinical Mycology with CD-ROM

Volumn , Issue , 2009, Pages 385-401

  Pfaller, Michael A ^a   Anaissie, Elias J ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052859357     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5680-5/00017-7     Document Type: Chapter

References (139)

1. Cushion M.T. Pneumocystis. Manual of Clinical Microbiology 2007, ASM Press, Washington, DC. 9th edn. P.C. Murray, E.J. Baron, J.H. Jorgensen, M.L. Landry, M.A. Pfaller (Eds.).
2. Bin C., Hui W., Peng W., et al. Clinical parameters and outcomes of Pneumocystis jirovecii pneumonia in non-HIV/AIDS patients. Clin Med J 2006, 119:234-237.
3. Dei-Cas E. Pneumocystis infections: the iceberg?. Med Mycol 2000, 38(suppl 1):23-32.
4. Mikaelsson L., Jacobsson G., Andersson R. Pneumocystis pneumonia-a retrospective study 1991-2001 in Gothenburg. Sweden. J Infect 2006, 53:260-265.
5. Morris A., Beard C.B., Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect 2002, 4:95-103.
6. Morris A., Lundgren J.D., Masur H., et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004, 10:1713-1720.
7. Patel N., Koziel H. Pneumocystis jirovecii pneumonia in adult patients with AIDS: treatment strategies and emerging challenges to antimicrobial therapy. Treat Respir Med 2004, 3:381-397.
8. Thomas C.F., Limper A.H. Pneumocystis pneumonia. N Engl J Med 2004, 350:2487-2498.
9. Wakefield A.E. Pneumocystis carinii. Br Med Bull 2002, 61:175-188.
10. Wazir J.F., Ansari N.A. Pneumocystis carinii infection: update and review. Arch Pathol Lab Med 2004, 128:1023-1027.
11. Kovacs J.A., Gill V.J., Meshnick S., Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001, 286:2450-2460.
12. Peterson J.C., Cushion M.T. Pneumocystis: not just pneumonia. Curr Opin Microbiol 2005, 8:383-398.
13. Teshale E.H., Hansen D.L., Wolfe M.I., et al. Reasons for lack of appropriate receipt of primary Pneumocystis jirovecii pneumonia prophylaxis among HIV-infected persons receiving treatment in the United States: 1994-2003. Clin Infect Dis 2007, 44:879-883. for the Adult and Adolescent Spectrum of HIV Disease Study Group.
14. de Boer M.G.J., Bruijnestijnavan Coppenraet L.E.S., Gassbeck A., et al. An outbreak of Pneumocystis jirovecii pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source?. Clin Infect Dis 2007, 44:1143-1149.
15. De Castro N., Neuville S., Sarfati C., et al. Occurrence of Pneumocystis jirovecii pneumonia after allogenic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 2005, 36:879-883.
16. Hocker B., Wendt C., Nahimana A., et al. Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis 2005, 11:330-332.
17. Manoloff E.S., Francioli P., Taffe P., et al. Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Emerg Infect Dis 2003, 9:132-134.
18. Rabodonirina M., Vanhems P., Couray-Targe S., et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis 2004, 10:1766-1773.
19. Roblot F., Imbert S., Godet C., et al. Risk factors analysis for Pneumocystis jirovecii pneumonia (PCP) in patients with haematological malignancies and pneumonia. Scand J Infect Dis 2004, 36:848-854.
20. Miller R., Huang L. Pneumocystis jirovecii infection. Thorax 2004, 59:731-733.
21. Redhead S.A., Cushion M.T., Frenkel J.K., Stringer J.R. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J. Eukaryot Microbiol 2006, 53:2-11.
22. Stringer J.R. Pneumocystis carinii: what is it, exactly?. Clin Microbiol Rev 1996, 9:489-498.
23. Stringer J.R. Pneumocystis. Int J Med Microbiol 2002, 292:391-404.
24. Stringer J.R., Beard C.B., Miller R.F., Wakefield A.E. A new name (Pneumocystis jirovecii) for Pneumocystis from humans. Emerg Infect Dis 2002, 8:891-896.
25. Beard C.B., Carter J.L., Keely S.P., et al. Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg Infect Dis 2000, 6:265-272.
26. Dumoulin A., Mazars E., Seguy N., et al. Transmission of Pneumocystis carinii disease from immunocompetent contacts of infected hosts to susceptible hosts. Eur J Clin Microbiol Infect Dis 2000, 19:671-678.
27. Larsen H.H., von Linstow M.L., Lundgren B., Hegh B., Westh H., Lundgren J.D. Primary Pneumocystis infection in infants hospitalized with acute respiratory tract infection. Emerg Infect Dis 2007, 13:66-72.
28. Medrano F.J., Montes-Cano M., Conde M., et al. Pneumocystis jirovecii in general population. Emerg Infect Dis 2005, 11:245-250.
29. Totet A., Respaldiza N., Pautard J.C., et al. Pneumocystis jirovecii genotypes and primary infection. Clin Infect Dis 2003, 36:1340-1342.
30. Totet A., Latouche S., Lacube P., et al. Pneumocystis jirovecii dihydropteroate synthase genotypes in immunocompetent infants and immunosuppressed adults, Amiens, France. Emerg Infect Dis 2004, 10:667-673.
31. Vidal S., de la Hora C., Martin J., et al. Pneumocystis jirovecii colonization in patients with interstitial lung disease. Clin Microbiol Infect 2006, 12:231-235.
32. Wakefield A.E., Lindley A.R., Ambrose H.E., et al. Limited asymptomatic carriage of Pneumocystis jirovecii in human immunodefiniciency virus-infected patients. J Infect Dis 2003, 187:901-908.
33. Stringer J.R. The identity of Pneumocystis carinii: not a single protozoan, but a diverse group of exotic fungi. Infect Angest Dis 1993, 2:109-117.
34. Edman J.C., Kovacs J.A., Masur H., Santi D.V., Elwood H.J., Sogin M.L. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988, 334:519-552.
35. Cushion M.T. Comparative genomics of Pneumocystis carinii with other protists: implication for life style. J Eukaryot Microbiol 2004, 51:30-37.
36. Alexopoulos C.J., Mims C.W., Blackwell M. Phylum Ascomycota. Archiasocomycetes. Introductory Mycology 1996, John Wiley, New York.
37. Erikkson O.E. Pneumocystis carinii, a parasite in lungs of mammals referred to a new family and order (Pneumocystidacae, Pneumocystidales, Ascomycota). Syst Ascomycetum 1994, 13:165-180.
38. Bruns T.D., Vilgalys R., Barns S.M., et al. Evolutionary relationships within the fungi: analysis of nuclear small subunit rRNA sequences. Mol Phylogenet Evol 1992, 1:231-241.
39. Van der Peer Y., Hendriles L., Goris A., et al. Evolution of basidiomycetous yeast as deduced from small ribosomal subunit RNA sequences. Syst Appl Microbiol 1992, 15:250-258.
40. Frenkel J.K. Pneumocystis jirovecii n. sp. from man: morphology, physiology, and immunology in relation to pathology. Natl Cancer Inst Monogr 1976, 43:13-30.
41. Frenkel J.K. Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD): a critical historical overview. J Ekaryot Microbiol 1999, 46(suppl):895-925.
42. Cushion M.T., Stringer J.R. Molecular and phenotypic description of Pneumocystis wakefieldiae sp. nov., a new species in rats. Mycologia 2004, 96:429-438.
43. Keely S.P., Fischer J.M., Cushion M.T., Stringer J.R. Phylogenetic identification of Pneumocystis murina sp. nov., a new species in laboratory mice. Microbiology 2004, 150:1153-1165.
44. Hughes W.T. Pneumocystis carinii vs Pneumocystis jirovecii: another misnomer (response to Stringer et al). Emerg Infect Dis 2003, 9:276-277.
45. Hawksworth D.L. Responsibility in naming pathogens: the case of Pneumocystis jirovecii, the causal agent of pneumocystis pneumonia. Lancet Infect Dis 2007, 7:3-5.
46. Ravinglione M.C. Extrapulmonary pneumocystosis: the first 50 cases. Rev Infect Dis 1990, 12. 1138-1138.
47. Cohen O.J., Stoeckle M.Y. Extrapulmonary Pneumocystis carinii infections in the acquired immunodeficiency syndrome. Arch Intern Med 1991, 151:1205-1214.
48. Procop G.W., Haddad S., Quinn J., et al. Detection of Pneumocystis jirovecii in respiratory specimens by four staining methods. J Clin Microbiol 2004, 42:3333-3335.
49. Cushion M.T. Pneumocystis: unraveling the cloak of obscurity. Trends Microbiol 2004, 12:243-249.
50. Yoshida Y., Shiota T., Yamada M., Matsumoto Y. Further light microscopic studies on morphology and development of Pneumocystis carinii. Zentralbl Backteriol Mkrobiol Hyg [A] 1981, 250:213-218.
51. Demanche C., Berthelemy M., Petit T., et al. Phylogeny of Pneumocystis carinii from 18 primate species confirms host specificity and suggests coevolution. J Clin Microbiol 2001, 39:2126-2133.
52. Beard C.B., Rouz P., Nevez G., et al. Strain typing methods and molecular epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004, 10:1729-1735.
53. Nevez G., Magois E., Duwat H., et al. Apparent absence of Pneumocystis jirovecii in healthy patients. Clin Infect Dis 2006, 42:e99-e101.
54. Pifer L.L., Hughes W.T., Stagno S., Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978, 61:35-41.
55. Peglow S.L., Smukin A.G., Linke M.J., et al. Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis 1990, 161:296-306.
56. Vargas S.L., Hughes W.T., Santolaya M.E., et al. Search for primary infection by Pneumocystis carinii in a cohort of normal. healthy infants 2001, 32:855-861.
57. Vargas S.L., Ponce C.A., Sanchez C.A., Ulloa A.V., Bustamante R., Juarez G. Pregnancy and asymptomatic carriage of Pneumocystis jirovecii. Emerg Infect Dis 2003, 9:605-606.
58. Pop S.M., Kolls J.K., Steele C. Pneumocystis: immune recognition and evasion. Int J Biochem Cell Biol 2006, 38:17-22.
59. Steele C., Shellito J.E., Kolls J.K. Immunity against the opportunistic fungal pathogen Pneumocystis. Med Mycol 2005, 43:1-19.
60. Stringer J.R. Antigenic variation in Pneumocystis. J Eukaryot Microbiol 2007, 54:8-13.
61. Telzak E.E., Armstrong D. Extrapulmonary infection and other unusual manifestations of Pneumocystis carinii. Pneumocystis carinii Pneumonia 1994, Marcel Dekker, New York. 2nd edn. P.D. Walzer (Ed.).
62. Lundgren B., Lebech M., Lind K., et al. Antibody response to a major human Pneumocystis carinii surface antigen in patients without evidence of immunosuppression and in patients with suspected atypical pneumonia. Eur J Clin Microbiol Infect Dis 1993, 12:105-109.
63. Wakefield A.E., Stewart T.J., Moxon E.R., et al. Infection with Pneumocystis carinii is prevalent in healthy Gambian children. Trans R Soc Trap Med Hyg 1990, 84:800-802.
64. Vargas S.L., Ponce C.A., Hughes W.T., et al. Association of primary Pneumocystis carinii infection and sudden infant death syndrome. Clin Infect Dis 1999, 29:1489-1493.
65. Sepkowitz K., Schluger N., Goldwin T., et al. DNA amplification in experimental pneumocystosis: characterization of serum Pneumocystis carinii DNA and potential Pneumocystis carinii carrier states. J Infect Dis 1993, 168:421-426.
66. Casanova-Cardiel L., Leibowitz M.J. Presence of Pneumocystis carinii DNA in pond water. J Eukaryot Microbiol 1997, 44:285.
67. Navin T.R., Rimland D., Lennox J.L., et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J Infect Dis 2000, 181:158-164.
68. Wakefield A.E. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora. J Clin Microbiol 1996, 34:1754-1759.
69. Kaneshiro E.S., Maiorano J.N. Survival and infectivity of Pneumocystis carinii outside the mammalian host. J Eukaryo Microbiol 1996, 43:355.
70. Olsson M., Lidman C., Latouche S., et al. Identification of Pneumocystis carinii f. sp. hominis gene sequence in filtered air in hospital environments. J Clin Microbiol 1998, 36:1737-1740.
71. Wakefield A.E. Detection of DNA sequences identical to Pneumocystis carinii in samples of ambient air. J Eukaryot Mircobiol 1994, 41:1165.
72. Huang L., Crothers K., Atzori C., et al. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis 2004, 10:1721-1728.
73. Stein C.R., Poale C., Kazanjian P., Meshnick S.R. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis 2004, 10:1760-1765.
74. Huang L., Beard C.D., Creasman J., et al. Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. J Infect Dis 2000, 182:1192-1198.
75. Miller R.F., Ambrose H.E., Wakefield A.E. Pneumocystis carinii f. sp. hominis DNA in immunocompetent healthcare workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 2001, 39:3877-3882.
76. Durand-Joly I., Soula F., Chabe M., et al. Long-term colonization with Pneumocystis jirovecii in hospital staffs: a challenge to prevent nosocomial pneumocystosis. Microbiology 2003, 50(suppl):614-615.
77. Nevez G., Totet A., Jounieaux V. Pneumocystis jirovecii internal transcribed spacer types in patients with pneumocytosis from the same French geographic region. J Clin Microbiol 2003, 41:181-186.
78. Walzer P.D., Perl D.P., Krogstad D.J., et al. Pneumocystis carinii pneumonia in the United States. Ann Intern Med 1974, 80:83-90.
79. Dungarwalla M., Marsh J.C., Tooze J.A., et al. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology. Ann Hematol 2007, 86:191-197.
80. Kolstad A., Holte H., Fossa A., et al. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007, 92:139-140.
81. Kalyoncu U., Karadag O., Akdogan A., et al. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scand J Infect Dis 2007, 39:475-478.
82. Kaur N., Mahl T.C. Pneumocystis jirovecii (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007, 52:1481-1484.
83. Harigai M., Koike R., Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007, 357:1874-1876.
84. Lahiff C., Khiaron O.B., Nolan N., et al. Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis. Ir J Med Sci 2007, 176:309-311.
85. Phair J., Munoz A., Detels R., Kaslow R., Rinaldo C., Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodefiniciency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990, 322:161-165.
86. Kaplan J.E., Hanson D., Dworkin M.S., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 30(suppl 1):S5-S14.
87. Kovacs A., Frederick T., Church J., Ellen A., Oxtoby M., Mascola L. CD4 T-lymphocyte counts and Pneumocystis carinii pneumonia in pediatric HIV infection. JAMA 1991, 265:1698-1703.
88. Amin M.B., Abrash M.P., Mezger E., et al. Systemic dissemination of Pneumocystis carinii in a patient with acquired immunodeficiency syndrome. Henry Ford Hosp Med J 1990, 38:68-71.
89. Stover D.E., Meduri G.U. Pulmonary function tests. Clin Chest Med 1988, 9:473.
90. Huang L., Stansell J., Osmond D., et al. Performance of an algorithm to detect Pneumocystis carinii pneumonia in symptomatic HIV-infected persons. Chest 1999, 115:1025.
91. Butt A.A., Michaels S., Kissinger P. The association of serum lactate dehydrogenase level with selected opportunistic infections and HIV progression. Int J Infect Dis 2002, 6:178.
92. Zaman M.K., White D.A. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia: diagnostic and prognostic significance. Am Rev Respir Dis 1988, 137:796.
93. Gruden J.F., Huang L., Turner J., et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. Am J Roentgenol 1997, 169:967.
94. Hartman T.E., Primack S.L., Muller N.L., Staples C.A. Diagnosis of thoracic complications in AIDS: accuracy of CT. Am J Roentgenol 1994, 162:547.
95. Hidalgo A., Falco V., Mauleon S., et al. Accuracy of high-resolution CT in distinguishing between Pneumocystis carinii pneumonia and non-Pneumocystis carinii pneumonia in AIDS patients. Eur Radiol 2003, 13:1179.
96. Tuazon C.N., Delaney M.D., Simm G.L., et al. Utility of gallium-67 scintigraphy and bronchial washings in the diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis 1985, 132:1087.
97. Zaman M.K., Wooten O.J., Suprahmanya B., et al. Rapid non-invasive diagnosis of Pneumocystis carinii from induced liquefied sputum. Ann Intern Med 1988, 109:7.
98. Cruciani M., Marcati P., Malena M., et al. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir 2002, 20:982.
99. Levine S.J., Masur H., Gill V.J., et al. Effect of aerosolized pentamidine prophylaxis on the diagnosis of Pneumocystis carinii pneumonia by induced sputum examination in patients infected wit the human immunodeficiency virus. Am Rev Respir Dis 1991, 144:760.
100. O'Donnell W.J., Pieciak W., Chertow G.M., et al. Clearance of Pneumocystis carinii cysts in acute P. carinii pneumonia. Assessment by serial sputum induction. Chest 1998, 114:1264.
101. Jules-Elysee K., Stover D.E., Zaman M.B., et al. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med 1990, 112:750.
102. Levine S.J., Kennedy D., Shelhamer J.H., et al. Diagnosis of Pneumocystis carinii pneumonia by multiple site-directed bronchoalveolar lavage with immunofluorescent monoclonal antibody staining in human immunodeficiency virus-infected patients receiving aerosolized pentamidine chemoprophylaxis. Am Rev Respir Dis 1992, 146:838.
103. Bustamante E.A., Levy H. Sputum induction compared with bronchoalveolar lavage by Ballard catheter to diagnose Pneumocystis carinii pneumonia. Chest 1994, 105:816.
104. Alvarez F., Bandi V., Stager C., Guntupalli K.K. Detection of Pneumocystis carinii in tracheal aspirates of intubated patients using calcofluor-white (Fungi-Fluor) and immunofluorescence antibody (Genetic Systems) stains. Crit Care Med 1997, 25:948.
105. Flori P., Belleta B., Durand F., et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jirovecii pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 2004, 53:603-607.
106. Durand-Joly I., Chabe M., Soula F., Delhaes L., Camus D., Dei-Cas E. Molecular diagnosis of Pneumocystis pneumonia. FEMS Immunol Microbiol 2005, 45:405-410.
107. Baselski V, Buchanan K, Carey R, et al. Survey of clinical microbiology laboratory workloads, productivity rates, and staffing vacancies. American Society for Microbiology Office of Public Health and Scientific Affairs, Washington, DC, 2005.
108. Helweg-Larsen J., Tsolaki A.G., Miller R.F., et al. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. QJM 1998, 91:813-820.
109. Marty F.M., Koo S., Bryar J and., Baden L.R. (1-3)beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007, 147:70-72.
110. Fujii T., Nakamura T., Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother 2007, 13:1-7.
111. Kawagishi N., Miyagi S., Satoh K., et al. Usefulness of beta-D glucan in diagnosing Pneumocystis carinii pneumonia and monitoring its treatment in a living-donor liver-transplant recipient. J Hepatobiliary Pancreat Surg 2007, 14:308-381.
112. Tasaka S., Hasegawa N., Kobayashi S., et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007, 131:1173-1180.
113. Shimizu A., Oka H., Matsuda T., et al. (1-3)-beta-D glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol 2005, 23:678-680.
114. Teramoto S., Sawaki D., Okada S., et al. Markedly increased plasma (1-3)-beta-D-glucan is a diagnostic and therapeutic indicator of Pneumocystis carinii pneumonia in a non-AIDS patient. J Med Microbiol 2000, 49:393-394.
115. Murakami T., Suzuki M., Okada S., et al. Pneumocystis carinii pneumonia associated with acquired immunodeficiency syndrome followed by KL-6, surfactant protein-D and beta-D-glucan in serum. Nihon Kokyuki Gakkai Zasshi 2000, 38:632-636.
116. Akamatsu N., Sugawara Y., Kaneko J., et al. Preemptive treatment of fungal infection based on plasma (1-3)beta-D-glucan levels after liver transplantation. Infection 2007, 35:346.
117. Hughes W.T. Transmission of Pneumocystis species among renal transplant recipients. Clin Infect Dis 2007, 44:1150-1151.
118. US Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health, 2nd edn. 2000. Available at:. http://www.healthypeople.gov/Publications/.
119. US Public Health Service (USPHS) Infectious Diseases Society of America (IDSA), USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials 2001, 2:193-554.
120. Schneider M.M., Nielsen T.L., Nelsing S., et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. J Infect Dis 1995, 171:1632.
121. El-Sadr W.M., Luskin-Hawk R., Yurik T.M., et al. Randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 1999, 29:775.
122. Bozzette S.A., Finkelstein D.M., Spector S.A., et al. Randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995, 332:693.
123. Hardy W.D., Feinberg J., Finkelstein D.M., et al. Controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group protocol 021. N Engl J Med 1992, 327:1842.
124. Carr A., Tindall B., Brew B.J., et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992, 117:106.
125. Leoung G, Standford J, Giordano M, et al. Randomized, double-blind trial of TMP/SMX dose escalation vs. direct challenge in HIV+ persons at risk for PCP and with prior treatment-limiting rash or fever (abstract LB10). Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997.
126. Para M.F., Finkelstein D., Becker S., et al. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr 2000, 24:337.
127. Ng V.L., Yajko D.M., Hadley W.K. Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997, 10:401-418.
128. CDC 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995, 44(No. RR-4):1.
129. Liegl U., Bogner J.R., Goebel F.D. Insulin-dependent diabetes mellitus following pentamidine therapy in a patient with AIDS. Clin Investig 1994, 72:1027.
130. Kovacs J.A., Gill V.J., Meshnick S., Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001, 286:2450.
131. Furuta T., Muramatsu H., Fujie A., Fujihara S. Therapeutic effect of a water soluble echinocandin compound on Pneumocystis pneumonia in animals. J Eukaryot Microbiol 1997, 44:535.
132. Kamboj M., Weinstock D., Sepkowitz K.A. Progression of Pneumocystis jirovecii pneumonia in patients receiving echinocandin therapy. Clin Infect Dis 2006, 43:e92-e94.
133. Lundberg B.E., Davidson A.J., Burman W.J. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS 2000, 14:2559.
134. Utili R., Durante-Mangoni E., Basilico C., et al. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe Pneumocystis pneumonia in solid organ transplant recipients. Transplantation 2007, 84:685-688.
135. Safrin S., Finkelstein D.M., Feinberg J., et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. Ann Intern Med 1996, 124:792.
136. Harstad T.W., Little B.B., Bawdon R.E., et al. Embryofetal effects of pentamidine isethionate administered to pregnant Sprague-Dawley rats. Am J Obstet Gynecol 1990, 163:912.
137. Benson C., Kaplan J., Masur H., et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clin Infect Dis 2005, 40:S131.
138. Helweg-Larsen J., Benfield T.L., Eugen-Olsen J., Lundgren J.D., Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999, 354:1347-1351.
139. Kessl J.J., Hill P., Lange B.B., et al. Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae. J Biol Chem 2004, 279:2817-2824.